LUMA GROUP

Thesis

Luma Group is a New York-based venture builder and investment firm founded in 2023, dedicated to advancing human health through strategic investments in technology-driven life sciences and healthcare companies. The firm's core mission is to partner with science-driven teams, providing not only capital but also strategic, operational, and scientific support to foster long-term progress. Luma Group leverages an AI system named LABI, which aggregates biological data, clinical trial data, and market dynamics to accelerate insight validation and uncover potential. Their investment focus is on the intersection of technology and life sciences, with a particular emphasis on biotechnology, health tech, medical devices, and digital health. They invest across pre-seed, seed, seed-plus, Series A, and Series B stages, typically leading or co-leading financings at Series A and B with check sizes ranging from $5 million to $20 million. While focusing on the US, they are open to global opportunities. Their strategy is technology-first, focusing on platform companies developing first-in-class or best-in-class assets, and they aim to partner with visionary founders, offering deep industry expertise, strategic guidance, and a strong network. Luma Group manages approximately $66 million in assets and has one fund, LumaBio I, which opened in July 2023.

Related lists

• Pre-seed AI investors
• Pre-seed Healthcare investors
• Seed-stage AI investors